Key Takeaways
- A painful quarter, with prices blamed: EBITDA margin collapsed to 9% from 12.9% YoY, net profit halved to ₹19 crore, and the chemical segment’s EBIT margin fell to just 0.8%, all driven by falling API selling prices and a one-time inventory hit from higher-cost raw materials.
- The non-ibuprofen pivot is working, but slowly: Non-ibuprofen export share doubled YoY to 24% of segment revenue, with a target of 50% in 2–3 years, yet sampling and approvals (Europe, Brazil, Korea) have not yet converted to material revenue.
- Management walked back its own margin guidance: After failing to hit the earlier 13–15% EBITDA target, management declared market volatility makes one-year forecasting “practically impossible,” a frank admission that resets investor expectations.
- A greenfield land buy signals ambition, but details are absent: The 101-acre site near Barnala was announced with no CAPEX figure, no product allocation between pharma and chemicals, and no commercialization before FY26 at the earliest.
- What to watch next quarter: Whether the “bottomed out” call on Ibuprofen, Paracetamol and Metformin prices actually translates to a recovery in realizations, and whether the US FDA inspection materializes with approvals for the ANDA-linked facilities.
Price & Margin Compression
- Ibuprofen prices drove the top-line miss: Domestic Ibuprofen prices corrected further during the quarter, and global demand remained low, so volume growth could not offset the price decline. Management now believes domestic prices have bottomed.
- Paracetamol and Metformin also under pressure: Prices for both have been on a downward trend for 2–3 quarters, though Paracetamol demand began increasing in the last month with a slight price uptick. Management hopes both have bottomed.
- Inventory markdown amplified the profit drop: Higher-cost acetic acid inventory purchased from China roughly two quarters ago was consumed or marked down during Q2, compressing margins beyond the selling-price effect. Management declined to quantify the impact but said it should not recur.
- Employee costs rose on one-time and structural factors: Variable pay for the prior year, paid in July 2024, added roughly ₹6 crore, while regular increments and new hires for upcoming projects and non-ibuprofen capacity expansion also lifted the expense base.
- Chemical segment margin nearly vanished: The segment’s EBIT margin fell to 0.8%, squeezed by lower average selling prices even as acetic acid and ethyl acetate input prices remained stable and the delta between them held.
Singh: “This market is very volatile. It is practically getting impossible to talk about what will be happening after one year. That is the main reason why we are not able to meet our guidance.”
Non-Ibuprofen Diversification
- Export share doubled, but from a small base: Non-ibuprofen export revenue rose from 10% to 24% of the segment over one year, with a 20–25% QoQ jump in the June quarter. The stated target is 50% export collection within 2–3 years.
- Regulatory approvals are accumulating, revenue is lagging: The company received European approval and other regulated-market approvals for non-ibuprofen products, and DMFs have been filed for new molecules. Customers filed ANDAs for Metformin and Fenofibrate, but sampling and approval processes have not yet converted to orders.
- Clopidogrel and Fenofibrate show better pricing: Among non-ibuprofen products, these two are seeing good price realization, and management says their prices have bottomed out and are recovering.
- Chinese Metformin approval opens a strategic door: The approval lets global players procure Metformin from India as an alternative to China, which management frames as a competitive opportunity to attract customers diversifying supply chains.
- No new product additions planned: The strategy is to stabilize existing products and increase their regulated-market penetration before considering portfolio expansion. Sitagliptin patent developments were described as premature and not discussed.
Mahajan: “Non-ibu segment, our target is around 50% export collection from non-ibu segment within upcoming 2 to 3 years which is presently around 23 to 24%.”
Competitive Landscape & SI Group Exit
- SI Group is exiting Ibuprofen manufacturing: The company officially declared to the SEC that it will close its US Ibuprofen facilities, citing high production costs and old technology, with a target closure by March 2025. Management does not expect a material impact on IOL, noting SI Group operated with smaller capacity in the US market.
- Backward integration is the stated moat: Management emphasized that 100% backward integration mitigates IOL’s locational disadvantage, a claim positioned as the core competitive strength in a commoditizing API market.
- Sanofi visited for Paracetamol inspection: A global Ibuprofen customer, Sanofi, inspected the Paracetamol plant, and management hopes this will lead to Paracetamol orders, though no commitment was confirmed.
Singh: “Our strength is that we are 100% backward integrated with respect to this. This mitigates all the locational disadvantage.”
Regulatory & Approval Pipeline
- US FDA inspection is expected but unscheduled: Management said the FDA has intimated it will inspect additional facilities for which ANDAs have already been filed by clients, but no timeline is confirmed. When the inspection happens, it is expected to cover Ibuprofen, Metformin and Fenofibrate sites, and subsequent ANDA approvals for other molecules may proceed without additional site inspections.
- European and other regulated approvals secured: Approvals from Europe, Brazil (SCEP) and Korea have been obtained for non-ibuprofen products, building the regulatory foundation for the export pivot.
- Utilization rates reflect product-level divergence: Ibuprofen utilization ran at 75–80%, while Metformin and Paracetamol ran at 90–95%, consistent with the demand and pricing trends across the portfolio.
Greenfield Expansion & CAPEX
- 101-acre land acquired near Barnala: The site sits on the Chandigarh-Bathinda National Highway, roughly 25 km from the existing plant, and is intended for a greenfield manufacturing facility for bulk APIs and organic chemicals. Commercialization is not expected until FY26 at the earliest, with regulatory approvals typically taking 6–8 quarters.
- CAPEX and product allocation are undecided: Management said the CAPEX for the new site is “yet to be seen” and that the split between pharmaceutical and chemical segments “is yet to be decided.” Some growth CAPEX currently in CWIP is expected to be capitalized within FY25.
- Total CAPEX of ₹133 crore includes the land purchase, technical developments and environmental-sector investments.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Non-ibuprofen export share | Reach 50% of segment export collection (from ~24% currently) | Within 2–3 years |
| H2 FY25 performance | Better than H1 FY25 | H2 FY25 |
| Q3 FY25 performance | Numbers expected to remain more or less same with slight improvement | Q3 FY25 |
| Inventory markdown | Higher-cost raw material impact should not recur | Entering quarter |
| Growth CAPEX capitalization | Some CAPEX in CWIP to be capitalised | Within FY25 |
| Greenfield site commercialization | Not before regulatory approvals (6–8 quarters typical) | FY26 at earliest |
| 2030 volume targets | On track for internal production volume projections; pricing and raw material volatility cannot be predicted | By 2030 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Total stand-alone income | ₹532 cr, vs ₹552 cr in Q2 FY24 and ₹510 cr in Q1 FY25 |
| EBITDA | ₹48 cr, vs ₹71 cr in Q2 FY24 and ₹58 cr in Q1 FY25 |
| EBITDA margin | 9%, vs 12.9% in Q2 FY24 and 11.4% in Q1 FY25 |
| Net profit | ₹19 cr, vs ₹38 cr in Q2 FY24 and ₹30 cr in Q1 FY25 |
| EBIT margin, chemical segment | 0.8% |
| Exports | ₹140 cr, vs ₹130 cr in Q2 FY24 and ₹150 cr in Q1 FY25 |
| CAPEX | ₹83 cr, vs ₹41 cr in Q2 FY24 and ₹50.8 cr in Q1 FY25 |
| R&D spend | ₹5.8 cr, vs ₹4.5 cr in Q2 FY24 and ₹4.7 cr in Q1 FY25 |
| Consolidated cash and bank balance | ₹157 cr as on 30th September 2024 |
| Ibuprofen global market share | 30–35% |
| Ibuprofen capacity utilization | 75–80% |
| Metformin and Paracetamol capacity utilization | 90–95% |
| Non-ibuprofen export share | 24% of non-ibu revenue, up from 10% a year ago |
| Non-ibuprofen export target | ~50% of non-ibu revenue within 2–3 years |
| Capital work in progress | ₹122 cr as on 30th September 2024 |